Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-790052 in chronic hepatitis C genotype 1
NCT01170962Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of daclatasvir in hepatitis C (HCV) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Extended Rapid Virologic Response at Week 12, Sustained Virologic Response at Week 24 and 1 more. Started Aug 2010; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01170962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170962.